Bimetallic gold-platinum nanoparticles as a drug delivery system coated with a new drug to target glioblastoma

Anastasia P. Stavropoulou; Maria Theodosiou; Elias Sakellis; Nikos Boukos; Giorgos Papanastasiou; Chengjia Wang; Adriana Tavares; Carlos Alcaide Corral; Dimitrios Gournis; Nikolaos Chalmpes; Oliviero L. Gobbo; Eleni K. Efthimiadou

doi:10.1016/j.colsurfb.2022.112463

Bimetallic gold-platinum nanoparticles as a drug delivery system coated with a new drug to target glioblastoma

Anastasia P. Stavropoulou, Maria Theodosiou, Elias Sakellis, Nikos Boukos, Giorgos Papanastasiou, Chengjia Wang, Adriana Tavares, Carlos Alcaide Corral, Dimitrios Gournis, Nikolaos Chalmpes, Oliviero L. Gobbo, Eleni K. Efthimiadou^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

A drug delivery nanosystem of noble bimetallic nanoparticles (NPs) which consists of Au NPs capped with Pt NPs (Au@Pt NPs) is constructed and functionalised with a quinazoline based small molecule (Au@Pt@Q NPs), acting as a theranostic agent against glioblastoma. Two different hydrothermal synthetic procedures for bimetallic Au@Pt NPs are presented and the resulting nanostructures are fully characterised by means of spectroscopic and microscopic methods. The imaging and targeting capacity of the new drug delivery system is assessed through fluorescent optical microscopy and cytotoxicity evaluations. The constructed Au@Pt NPs consist a monodispersed colloidal solution of 25 nm with photoluminescent, fluorescent and X-Ray absorption properties that confirm their diagnostic potential. Haemolysis testing demonstrated that Au@Pt NPs are biocompatible and fluorescent microscopy confirmed their entering the cells. Cytological evaluation of the NPs through MTT assay showed that they do not inhibit the proliferation of control cell line HEK293, whereas they are toxic in U87MG, U251 and D54 glioblastoma cell lines; rendering them selective targeting agents for treating glioblastoma.

Original language	English
Pages (from-to)	112463
Journal	Colloids and Surfaces B: Biointerfaces
Volume	214
DOIs	https://doi.org/10.1016/j.colsurfb.2022.112463
Publication status	Published - 16 Mar 2022

Access to Document

10.1016/j.colsurfb.2022.112463

Manuscript file FINALAccepted author manuscript, 1.24 MBLicence: CC BY-NC-ND

https://linkinghub.elsevier.com/retrieve/pii/S0927776522001461

Edinburgh Preclinical Imaging
Moran, C. (Manager), Thomson, A. (Manager), Lennen, R. J. (Manager), Tavares, A. (Manager), Alcaide-Corral, C. J. (Manager), Morgan, T. (Other), Cranston, I. (Other) & O'Rourke, K. (Other)
School of Neurological and Cardiovascular Sciences
Facility/equipment: Facility

Cite this

Stavropoulou, A. P., Theodosiou, M., Sakellis, E., Boukos, N., Papanastasiou, G., Wang, C., Tavares, A., Corral, C. A., Gournis, D., Chalmpes, N., Gobbo, O. L., & Efthimiadou, E. K. (2022). Bimetallic gold-platinum nanoparticles as a drug delivery system coated with a new drug to target glioblastoma. Colloids and Surfaces B: Biointerfaces, 214, 112463. https://doi.org/10.1016/j.colsurfb.2022.112463

@article{0fd2d7cef38a4634a73f7bae264a2af9,

title = "Bimetallic gold-platinum nanoparticles as a drug delivery system coated with a new drug to target glioblastoma",

abstract = "A drug delivery nanosystem of noble bimetallic nanoparticles (NPs) which consists of Au NPs capped with Pt NPs (Au@Pt NPs) is constructed and functionalised with a quinazoline based small molecule (Au@Pt@Q NPs), acting as a theranostic agent against glioblastoma. Two different hydrothermal synthetic procedures for bimetallic Au@Pt NPs are presented and the resulting nanostructures are fully characterised by means of spectroscopic and microscopic methods. The imaging and targeting capacity of the new drug delivery system is assessed through fluorescent optical microscopy and cytotoxicity evaluations. The constructed Au@Pt NPs consist a monodispersed colloidal solution of 25 nm with photoluminescent, fluorescent and X-Ray absorption properties that confirm their diagnostic potential. Haemolysis testing demonstrated that Au@Pt NPs are biocompatible and fluorescent microscopy confirmed their entering the cells. Cytological evaluation of the NPs through MTT assay showed that they do not inhibit the proliferation of control cell line HEK293, whereas they are toxic in U87MG, U251 and D54 glioblastoma cell lines; rendering them selective targeting agents for treating glioblastoma. ",

author = "Stavropoulou, \{Anastasia P.\} and Maria Theodosiou and Elias Sakellis and Nikos Boukos and Giorgos Papanastasiou and Chengjia Wang and Adriana Tavares and Corral, \{Carlos Alcaide\} and Dimitrios Gournis and Nikolaos Chalmpes and Gobbo, \{Oliviero L.\} and Efthimiadou, \{Eleni K.\}",

note = "Funding Information: It is also based upon work from COST Action 17140 {"}Cancer Nanomedicine - from the bench to the bedside{"}, Nano2clinic, supported by COST (European Cooperation in Science and Technology). We acknowledge support of this work by the project {\textquoteleft}{\textquoteleft} National Infrastructure in Nanotechnology, Advanced Materials and Micro-/Nanoelectronics of Ioannina University” ( MIS-5002772 ) which is implemented under the Action {\textquoteleft}{\textquoteleft}Reinforcement of the Research and Innovation Infrastructure”, funded by the Operational Programme {\textquoteleft}{\textquoteleft}Competitiveness, Entrepreneurship and Innovation” (NSRF 2014–2020 ) and co-financed by Greece and the European Union ( European Regional Development Fund ). Publisher Copyright: {\textcopyright} 2022",

year = "2022",

month = mar,

day = "16",

doi = "10.1016/j.colsurfb.2022.112463",

language = "English",

volume = "214",

pages = "112463",

journal = "Colloids and Surfaces B: Biointerfaces",

issn = "0927-7765",

publisher = "Elsevier",

}

Stavropoulou, AP, Theodosiou, M, Sakellis, E, Boukos, N, Papanastasiou, G, Wang, C, Tavares, A, Corral, CA, Gournis, D, Chalmpes, N, Gobbo, OL & Efthimiadou, EK 2022, 'Bimetallic gold-platinum nanoparticles as a drug delivery system coated with a new drug to target glioblastoma', Colloids and Surfaces B: Biointerfaces, vol. 214, pp. 112463. https://doi.org/10.1016/j.colsurfb.2022.112463

TY - JOUR

T1 - Bimetallic gold-platinum nanoparticles as a drug delivery system coated with a new drug to target glioblastoma

AU - Stavropoulou, Anastasia P.

AU - Theodosiou, Maria

AU - Sakellis, Elias

AU - Boukos, Nikos

AU - Papanastasiou, Giorgos

AU - Wang, Chengjia

AU - Tavares, Adriana

AU - Corral, Carlos Alcaide

AU - Gournis, Dimitrios

AU - Chalmpes, Nikolaos

AU - Gobbo, Oliviero L.

AU - Efthimiadou, Eleni K.

N1 - Funding Information: It is also based upon work from COST Action 17140 "Cancer Nanomedicine - from the bench to the bedside", Nano2clinic, supported by COST (European Cooperation in Science and Technology). We acknowledge support of this work by the project ‘‘ National Infrastructure in Nanotechnology, Advanced Materials and Micro-/Nanoelectronics of Ioannina University” ( MIS-5002772 ) which is implemented under the Action ‘‘Reinforcement of the Research and Innovation Infrastructure”, funded by the Operational Programme ‘‘Competitiveness, Entrepreneurship and Innovation” (NSRF 2014–2020 ) and co-financed by Greece and the European Union ( European Regional Development Fund ). Publisher Copyright: © 2022

PY - 2022/3/16

Y1 - 2022/3/16

N2 - A drug delivery nanosystem of noble bimetallic nanoparticles (NPs) which consists of Au NPs capped with Pt NPs (Au@Pt NPs) is constructed and functionalised with a quinazoline based small molecule (Au@Pt@Q NPs), acting as a theranostic agent against glioblastoma. Two different hydrothermal synthetic procedures for bimetallic Au@Pt NPs are presented and the resulting nanostructures are fully characterised by means of spectroscopic and microscopic methods. The imaging and targeting capacity of the new drug delivery system is assessed through fluorescent optical microscopy and cytotoxicity evaluations. The constructed Au@Pt NPs consist a monodispersed colloidal solution of 25 nm with photoluminescent, fluorescent and X-Ray absorption properties that confirm their diagnostic potential. Haemolysis testing demonstrated that Au@Pt NPs are biocompatible and fluorescent microscopy confirmed their entering the cells. Cytological evaluation of the NPs through MTT assay showed that they do not inhibit the proliferation of control cell line HEK293, whereas they are toxic in U87MG, U251 and D54 glioblastoma cell lines; rendering them selective targeting agents for treating glioblastoma.

AB - A drug delivery nanosystem of noble bimetallic nanoparticles (NPs) which consists of Au NPs capped with Pt NPs (Au@Pt NPs) is constructed and functionalised with a quinazoline based small molecule (Au@Pt@Q NPs), acting as a theranostic agent against glioblastoma. Two different hydrothermal synthetic procedures for bimetallic Au@Pt NPs are presented and the resulting nanostructures are fully characterised by means of spectroscopic and microscopic methods. The imaging and targeting capacity of the new drug delivery system is assessed through fluorescent optical microscopy and cytotoxicity evaluations. The constructed Au@Pt NPs consist a monodispersed colloidal solution of 25 nm with photoluminescent, fluorescent and X-Ray absorption properties that confirm their diagnostic potential. Haemolysis testing demonstrated that Au@Pt NPs are biocompatible and fluorescent microscopy confirmed their entering the cells. Cytological evaluation of the NPs through MTT assay showed that they do not inhibit the proliferation of control cell line HEK293, whereas they are toxic in U87MG, U251 and D54 glioblastoma cell lines; rendering them selective targeting agents for treating glioblastoma.

U2 - 10.1016/j.colsurfb.2022.112463

DO - 10.1016/j.colsurfb.2022.112463

M3 - Article

SN - 0927-7765

VL - 214

SP - 112463

JO - Colloids and Surfaces B: Biointerfaces

JF - Colloids and Surfaces B: Biointerfaces

ER -

Bimetallic gold-platinum nanoparticles as a drug delivery system coated with a new drug to target glioblastoma

Abstract

Access to Document

Fingerprint

Equipment

Edinburgh Preclinical Imaging

Cite this